Summary
We have tested the efficiency of GM-CSF to mobilize peripheral blood progenitor cells (PBPC) and evaluated the hematological reconstitution after GM-CSF primed-PBPC infusion following myeloablative therapy. Twenty three patients suffering from hematological malignancies were included in this study. Starting 24 hours after completion of a standard dose chemotherapy including vindesine, cyclophosphamide, adriblastine, prednisone, (VCAP), 5 (μg/kg sub-cutaneous daily dose GM-CSF was given for a median time of 14 days followed by three consecutives cycles of leukapheresis. Fifteen of these 23 patients underwent GM-CSF primed-PBPC autotransplantation following high dosed intensification regimen. PBPC collection and hematopoietic recovery were compared with a 15 patients control group who did not receive GM-CSF. No marrow or growth factors were administred after PBPC reinfusion in the two groups. VCAP/GM-CSF mobilization induced significantly higher yields of CFU-GM (3.8 fold) than did VCAP mobilization alone, 19×104/kg (2–73) vs 5×104/kg (2–27), (p<0.005). The median number of days to achieve 1.109/l neutrophils, platelet count >20.109/l and >50.109/l was significantly lower in the GM-CSF group than in the control group, respectively 13 vs 19 days (p=0.04), 15.5 vs 27 days (p<0.02), 19 vs 51 days (p<0.01). When compared with the control group, transfusion requirements and median of hospital stay were both significantly decreased for the patients receiving GM-CSF primed-PBPC. Our study confirms that infusion of GM-CSF primed-PBPC as a sole source of hematopoietic support improves hematopoietic reconstitution following myeloablative therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Petersen FB, Appelbaum FR, Hill R, Fischer LD, Bigelow CL, Sanders JE, Sullivan KM, Bensinger WI, Witherspoon RP, Storb R, Clift RA, Fefer A, Press OW, Weiden PL, Singer J, Thomas ED, Buckner CD (1990) Autologous marrow transplantation for malignant lymphoma. A report of 101 cases from Seattle. J Clin Oncol 8:638–647
Armitage JO (1989) Bone marrow transplantation in the treatment of patients with lymphoma. Blood 73:1749–1758
Appelbaum FR (1989) Marrow transplantation in the treatment of patients with lymphoma. Curr Opin Oncol 1:47–54
Takvorian T, Canellos GP, Ritz J, Freedman AS, Anderson KC, Mauch P, Tarbell N, Coral F, Daley H, Yeap B (1987) Prolonged disease-free survival after bone marrow transplantation in patients with NHL with a poor prognosis. N Engl J Med 316:1499
Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD (1988) Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 71:723–727
William SF, Britan JD, Richards JM, De Christopher PJ, Barker E, Conant J, Golomb HM, Orlina AR (1990) Peripheral blood-derived stem cell collections for use in autologous transplantation after high-dose chemotherapy: an alternative approach. Bone Marrow Transplant 5:129–133
Lasky LC, Hurd DD, Smith JA, Haak R (1989) Peripheral blood stem cell collection and use in Hodgkin's disease. Comparison with marrow in autologous transplantation. Transfusion 29:323–326
Kessinger A, Armitage JO (1991) The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 77:211–213
Advani R, Chao NJ, Horning SJ, Blume KG, Ahn DK, Fleming N, Bonnen E, Greenberg P (1992) Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Ann Intern Med 116:183–189
Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD (1988) Granulocyte-macrophage colony-stimulating factor expands the circulating hematopoietic progenitor cell compartment in man. Lancet 1:1194–1198
Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, Mc Grath KM, Morsty G, Fox RM (1992) Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1:640–644
Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Pireli A, Bonadonna G (1989) Granulocyte-macrophage colony-stimulating factor to harvest circulating haematopoietic stem cells for autotransplantation. Lancet 2:580–585
Nemunaitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM, Freedman AS, Onetto N, Gillis S, Odette D, Gold M, Buckner C, Hansen J, Ritz J, Applebaum F, Armitage J, Nadler N (1991) Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 324:1773–1778
Chao NJ, Schriber JR, Grimes K, Long GD, Negrin RS, Raimondi CM, Horning SJ, Brown SL, Miller L, Blume KG (1993) Granulocyte colony-stimulating factor “mobilized” peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 8:2031–2035
Haas R, Ehrhardt R, Witt B, Goldschmidt H, Hohaus S, Pforsich, Ehrlich H, Farber L, Hunstein W (1993) Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulating factor following high-dose chemotherapy in non-Hodgkin's lymphoma. Bone Marrow Transplant 12:643–649
Teshima T, Harada M, Takamatsu Y, Makino K, Inaba S, Akashi K, Kondo S, Tanaka T, Ishii E, Niho Y (1993) Granulocyte colony-stimulating factor (G-CSF)-induced mobilization of circulating haemopoietic stem cells. Br J Haematol 84:570–573
Peters WP, Rosner G, Ross M, Vredenburgh J, Meisenberg B, Gilbert C, Kurtzberg J (1993) Comparative effects of granulocyte-macrophage colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 81:1709–1719
Bensinger W, Singer J, Appelbaum F, Lilleby K, Longin K, Rowley S, Clarke E, Clift R, Hansen J, Shields T, Storb R, Weaver C, Weiden P, Buckner CD (1993) Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte-stimulating factor. Blood 81:3158–3163
Pettengel R, Morgenstern G, Chang J (1993) Peripheral blood progenitor cell (PBPC): the single apheresis transplant fifth international conference on malignant lymphoma. Lugano (abstract 36)
Elias AD, Ayash L, Anderson KC, Hunt M, Wheeler C, Schwartz G, Tepler I, Mazanet R, Lynch C, Pap S, Pelaez J, Reich E, Critchlow J, Demetri G, Bibbo J, Schnipper L, Griffin JD, Frei E III, Antman KH (1992) Mobilization of peripheral blood progenitor cells by chemotherapy and granulocytemacrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 79:3036–3044
Bolwell BJ, Fishleder A, Andresen SW, Lichtin AE, Koo A, Yanseens T, Burrwell R, Baucco P, Green R (1993) G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment. Bone Marrow Transplant 12:609–614
Shimazaki C, Oku N, Uchiyama H, Yamagata N, Tatsumi T, Hirata E, Ashihara (1994) Effect of granulocyte colony-stimulating factor on hematopoietic recovery after peripheral blood progenitor cell transplantation. Bone Marrow Transplant 13:271–275
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lamy, T., Drenou, B., Grulois, I. et al. Improvement of hematologic recovery after high-dose intensification using peripheral blood progenitor cells (PBPC) mobilized by chemotherapy and GM-CSF. Ann Hematol 69, 297–302 (1994). https://doi.org/10.1007/BF01696558
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01696558